Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision and targeted therapies. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we conducted the FUTURE trial (ClinicalT...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Res
Hlavní autoři: Jiang, Yi-Zhou, Liu, Yin, Xiao, Yi, Hu, Xin, Jiang, Lin, Zuo, Wen-Jia, Ma, Ding, Ding, Jiahan, Zhu, Xiaoyu, Zou, Jianjun, Verschraegen, Claire, Stover, Daniel G., Kaklamani, Virginia, Wang, Zhong-Hua, Shao, Zhi-Ming
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Singapore 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8027015/
https://ncbi.nlm.nih.gov/pubmed/32719455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41422-020-0375-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky